MacDonald-Clink joins Arecor top team
Cambridge biopharma company Arecor has made a key appointment as it bids to broaden and accelerate partnership deals.
Jim MacDonald-Clink has been unveiled as VP for Business Development having joined from Mundipharma; he has been charged with extending and expanding areas of growth.
At Mundipharma, he was responsible for business development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements.
His experience includes acquisition, licensing and strategic partnering initiatives in specialist therapy areas as well as various roles in R & D, medical and commercial functions.
He has over 25 years of experience in healthcare with Mundipharma, Astellas Pharma, Fujisawa, Institute of Cancer Research at the Royal Marsden and Institute of Child Health at Great Ormond Street Hospital, London, UK.
Sarah Howell, Arecor’s CEO, said: “Jim joins Arecor at a pivotal time in our evolution. He brings 25 years of experience and expertise in business development within the pharma industry as well as in the broader areas of pharma development and commercialisation.
“He will play a key role in delivering our strategic business development plans as we strive to meet our ambitious goal of transforming patient care by bringing innovative medicines to market using our Arestat™ technology.”
Through the enhancement of existing medicines using Arestat, Arecor is developing a broad portfolio of therapies as part of a proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.
Its treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
Arestat is described as a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides.
Arecor’s proprietary products leverage Arestat to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates.